Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2018 4
2019 2
2020 1
2022 2
2023 6
2024 5
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG; International Consortium on Myelodysplastic Syndromes. Komrokji RS, et al. Among authors: kim tk. Lancet Haematol. 2024 Nov;11(11):e862-e872. doi: 10.1016/S2352-3026(24)00251-5. Epub 2024 Oct 9. Lancet Haematol. 2024. PMID: 39393368 Review.
We investigated the biological continuum between myelodysplastic syndromes with more than 10% bone marrow blasts and acute myeloid leukaemia, and found only a partial overlap in genetic features. After the survey, myelodysplastic syndromes with low blasts (ie, less than 5% …
We investigated the biological continuum between myelodysplastic syndromes with more than 10% bone marrow blasts and acute myeloid leukae …
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo VK, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Xie Z, Xu ML, Hasserjian RP, Loghavi S. Aakash F, et al. Among authors: kim tk. Mod Pathol. 2024 Dec;37(12):100615. doi: 10.1016/j.modpat.2024.100615. Epub 2024 Sep 23. Mod Pathol. 2024. PMID: 39322118 Free article. Review.
PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.
Kim TK, Han X, Hu Q, Vandsemb EN, Fielder CM, Hong J, Kim KW, Mason EF, Plowman RS, Wang J, Wang Q, Zhang JP, Badri T, Sanmamed MF, Zheng L, Zhang T, Alawa J, Lee SW, Zeidan AM, Halene S, Pillai MM, Chandhok NS, Lu J, Xu ML, Gore SD, Chen L. Kim TK, et al. J Clin Invest. 2024 Feb 1;134(3):e164325. doi: 10.1172/JCI164325. J Clin Invest. 2024. PMID: 38060328 Free PMC article.
Acute myeloid leukemia (AML) presents a pressing medical need in that it is largely resistant to standard chemotherapy as well as modern therapeutics, such as targeted therapy and immunotherapy, including anti-programmed cell death protein (anti-PD) therapy. ...
Acute myeloid leukemia (AML) presents a pressing medical need in that it is largely resistant to standard chemotherapy as well as mod …
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Borate U, et al. Among authors: kim tk. Blood. 2025 Mar 27;145(13):1369-1381. doi: 10.1182/blood.2023023717. Blood. 2025. PMID: 40146152 Free PMC article.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Stahl M, et al. Among authors: kim tk. Blood Rev. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. Blood Rev. 2023. PMID: 37704469 Review.
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK, Gore SD, Zeidan AM. Kim TK, et al. Semin Hematol. 2015 Jul;52(3):172-83. doi: 10.1053/j.seminhematol.2015.04.003. Epub 2015 Apr 8. Semin Hematol. 2015. PMID: 26111464 Free PMC article. Review.
Epigenetic modulation is a part of normal physiologic development; its dysregulation is an important mechanism of pathogenesis of some cancers, including acute myeloid leukemia (AML). Despite significant progress in understanding the pathogenesis of AML, therapeutic option …
Epigenetic modulation is a part of normal physiologic development; its dysregulation is an important mechanism of pathogenesis of some cance …
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM. Bewersdorf JP, et al. Among authors: kim tk. Ann Hematol. 2024 Jan;103(1):105-116. doi: 10.1007/s00277-023-05552-4. Epub 2023 Dec 1. Ann Hematol. 2024. PMID: 38036712 Free PMC article. Clinical Trial.
Patients with myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) with hypomethylating agent failure have a poor prognosis. Myeloid-derived suppressor cells (MDSCs) can contribute to MDS progression and mediate resistance to anti-PD1 therapy. ...
Patients with myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) with hypomethylating agent failure have a poo …
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Bewersdorf JP, et al. Among authors: kim tk. Blood Rev. 2023 Jul;60:101072. doi: 10.1016/j.blre.2023.101072. Epub 2023 Mar 11. Blood Rev. 2023. PMID: 36934059 Review.
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.
Stahl M, Kim TK, Zeidan AM. Stahl M, et al. Among authors: kim tk. World J Stem Cells. 2016 Oct 26;8(10):316-331. doi: 10.4252/wjsc.v8.i10.316. World J Stem Cells. 2016. PMID: 27822339 Free PMC article. Review.
The existence of cancer stem cells has been well established in acute myeloid leukemia. Initial proof of the existence of leukemia stem cells (LSCs) was accomplished by functional studies in xenograft models making use of the key features shared with normal hematopo …
The existence of cancer stem cells has been well established in acute myeloid leukemia. Initial proof of the existence of leukemia …
LAIR-1 agonism as a therapy for acute myeloid leukemia.
Lovewell RR, Hong J, Kundu S, Fielder CM, Hu Q, Kim KW, Ramsey HE, Gorska AE, Fuller LS, Tian L, Kothari P, Paucarmayta A, Mason EF, Meza I, Manzanarez Y, Bosiacki J, Maloveste K, Mitchell N, Barbu EA, Morawski A, Maloveste S, Cusumano Z, Patel SJ, Savona MR, Langermann S, Myint H, Flies DB, Kim TK. Lovewell RR, et al. Among authors: kim tk. J Clin Invest. 2023 Nov 15;133(22):e169519. doi: 10.1172/JCI169519. J Clin Invest. 2023. PMID: 37966113 Free PMC article.
Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to regulate LSC survival; however, the therapeutic potential of this pathway remains unexplored. ...
Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immu …
24 results